Yuuichi Sakurai

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino et al. · Gut · 2016 · 420 citations · Full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Yuuichi Sakurai, Akira Nishimura, Gale Kennedy et al. · Clinical and Translational Gastroenterology · 2015 · 188 citations · Full text

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu et al. · World Journal of Gastroenterology · 2018 · 104 citations · Full text

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino et al. · Current Therapeutic Research · 2016 · 71 citations · Full text

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino et al. · Therapeutic Advances in Gastroenterology · 2017 · 62 citations · Full text